BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee.Dr. Duncan is a biotechnology strategist, board director and former top-ranked Wall Street biotechnology analyst with nearly...

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.

From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team

Winter Park, Florida--(Newsfile Corp. - August 31, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced that its introductory innovation session earlier this month at Full Sail University delivered exactly the spark the Company was looking for — and that Adia Med has already assembled a social media team of interns to convert that momentum into a new era of organic marketing.From Full Sail...

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose study for neovascular Age-related Macular Degeneration (nAMD).

T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors

MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma BEIJING, Aug. 31, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") today announced that its investigational allogeneic CAR-T cell therapy...

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparedness and access to life-saving interventions. i As opioid overdose remains a significant global public health challenge, Emergent is focused on empowering people with the information and tools needed to act in the event of an opioid overdose emergency.

Life Sciences Quality Management Software Market: The Push Toward Connected, Scalable Quality Infrastructure

Quality is not optional in the life sciences industry — it is the foundation on which patient safety, regulatory approval, and business survival are built. [read full press release...]

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted...

Aviva Aesthetics Expands Greater Phoenix and Scottsdale Presence Through Partnership with Perfect Skin Center

Physician-led practice with a 26-year legacy joins the entrepreneur-owned platform, adding two Phoenix-area locations in Tempe and Scottsdale CHICAGO, Aug. 31, 2026 /PRNewswire-PRWeb/ -- Aviva Aesthetics, the nation's only entrepreneur-owned medical aesthetics platform, today announced a...

How To Cover Medical Costs That Insurance Doesn't Cover

Pomerantz LLP Announces Securities Class Action Lawsuit Against Fractyl ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 31, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..

Dr. Philip S. Low Inducted into 2026 ACS Division of Medicinal Chemistry Hall of Fame

Purdue drug discovery pioneer and LIFT founder recognized posthumously for targeted-therapy research that yielded three FDA-approved medicines WEST LAFAYETTE, Ind., Aug. 31, 2026 /PRNewswire-PRWeb/ -- The Low Institute for Therapeutics (LIFT) today announced that its Founder, the late Dr....